InvestWiser

CellaVision AB

CEVINasdaq StockholmHealthcareMarket value 4.9 bn SEK
203.50SEK +0.5%
last day · Price as of 18 November 2026

The answer first

Does CellaVision beat the market?

Yes, CellaVision has beaten the market over the last year.

CellaVision+35.4%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 84% of Nordic stocks

    • Quality99
    • Value13
    • Trend91

    No. 21 of 195 in healthcare

  • Expectations in the price

    High expectations

    For the share to return about 9% a year from today's price, the cash CellaVision keeps must grow about 12% a year for 10 years.

Max for seven days

Follow CellaVision with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on CellaVision

From today, at a price of 203.50 SEK. Write why you follow CellaVision, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about CellaVision

Your first answer is free, no account needed.

Do you own CellaVision, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with CellaVision and a few more. Free, no card.

Past year against the exchange and Super Stock
CellaVision+35.4%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • CellaVision has risen 35.4% over the past year, including dividends.
  • Overall, CellaVision ranks better than 84% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 67.3%. The price is 56.0% below its peak now.

What do analysts think of CellaVision?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

84

Quality, value and trend together. Better than 84% of Nordic stocks.

No. 21 of 195 in healthcare

Quality99
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 5 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.06
  • Asset turnoverSales divided by everything the company owns0.64
  • Return on equityProfit divided by equity+14.8%
  • Cash conversionOperating cash flow divided by profit1.53

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value13
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 127 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity5.1
  • P/SPrice divided by sales6.3
  • P/EPrice divided by earnings34.7
  • P/CFPrice divided by operating cash flow22.7

The ranking is built on P/E, P/B and P/S.

Trend91
The share price · Technical: the price trend

High Tailwind in the share price: it has risen more than most over the last year.

No. 23 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+24.4%
  • 6 months+63.6%
  • 9 months+36.1%
  • 12 months+35.4%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+24.2%
3 years, per year
+10.8%
5 years, per year
−10.9%
10 years, per year
+10.5%
Largest fall, 3 years
−67.3%
From a peak to the bottom
From the peak now
−56.0%
How far the price is from the peak
Volatility, 1 year
41.4%
How much the price swings over a year
Beta, 1 year
0.76
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own CellaVision

15 funds we follow own CellaVision. The share is how much of the fund the stock makes up.

  • Norway1
  • Sweden14

From the funds' latest known holdings.

About CellaVision

CellaVision AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 250 employees.

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials.

See the full analysis of CellaVision.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market